Meet Our Providers

Kambiz Dardashti, MD, FACS

kambitz dardashti

Dr. Dardashti earned his undergraduate and medical degrees at UCLA where he was a Regent Scholar.  He went to New York to complete his urology residency at Cornell Medical Center and Memorial Sloan Kettering Cancer Center.  Among numerous other awards, Dr. Dardashti was a grant recipient of the American Foundation for Urologic Disease.  He has served as Chief of Urology at Providence Little Company of Mary as well we voluntary teaching faculty at Harbor UCLA medical center, He began private practice in urology in 2002 and has special interests in newest treatments for advanced prostate cancer, minimally Invasive treatments for enlarged prostate,  laparoscopic surgery, and complex stone disease He is certified by the American Board of Urology and is Fellow of the American College of Surgeons. His many recognitions and awards include Los Angeles Magazine Top Doctors Award, as well as the very prestigious Castle Connolly Top Doctors award, given to the top 5% physicians in United States.

In Practice

Since 2002

Languages

English, Farsi

Medical School

  • UCLA, BS Biology with Honors, 1990
  • UCLA School of Medicine, Doctor of Medicine, 1995

Residency

  • Cornell Medical Center, Internship in Surgery, 1996
  • Cornell Medical Center, Urology, 2001
  • American Urologic Association
  • Western Section AUA
  • American Board of Urology
  • Fellow, American College of Surgeons
  • Minimally invasive Prostate treatment
  • Laparoscopic Surgery
  • Urologic Cancer
  • Complex Stone Disease
  • Incontinence
  • Oncology
  • Advanced Prostate Cancer

Lawrence Flechner, MD, PhD, FACS

lawrence flechner

Dr. Lawrence Flechner originally hails from San Francisco. He graduated Phi Beta Kappa from Stanford University, majoring in History—a passion he pursues to this day—while at the same time completing his premedical studies. He then won a coveted scholarship to spend a year researching molecular mechanisms of Cancer at the National Institutes of Health in Bethesda, Maryland.  Inspired to connect medical research with patient care, he went on to receive MD and PHD degrees at UCSD and The Salk Institute in La Jolla, California. Under the mentorship of the National Academy Sciences Member Marc Montminy at The Salk, Dr. Flechner made significant advances in our fundamental understanding of sugar metabolism and Diabetes. Specifically, he helped characterize a gene that is essential for blood sugar control. This important work made publication in the prestigious journal Nature. Dr. Flechner’s career next took him to top ranked UCSF Department of Urology, a place of historic significance in shaping the practice of Urology. Dr. Flechner trained under the close mentorship of Doctors Jack McAnanich, Peter Carroll, Marshall Stoller, and Tom Lue, each titans in their respective fields of Urology. At UCSF, Dr. Flechner gained extensive experience in the management of all aspects of benign and oncologic Urology, with expertise and versatility in conventional open, laparoscopic, and robotic surgery. After completing his training in 2012, Dr. Flechner was recruited to become a Partner at the Urology Institute of the South Bay. He is married to a successful leader in Education from Los Angeles, and they have two young children. Dr. Flechner is among the busiest robotic surgeons in the South Bay, and serves on the Robotic Surgery Committee at Torrance Memorial Hospital. A compassionate and dedicated surgeon, he serves on the Advisory Board of the Cancer Support Community of Redondo Beach, and on the Manhattan Beach Rotary Club. When not working, he enjoys organizing family adventures around the world, jogging on the Strand, scuba diving, archaeology, and being a present Dad to his growing kids.

In Practice

Since 2012

Languages

English, Spanish, Hebrew

Medical School

  • Stanford University, BA History with high honors, 1993-1997
  • UC San Diego, Doctor of Medicine, 1998-2006

Residency

  • UC San Francisco School of Medicine, Internship in Surgery, 2007
  • UC San Francisco School of Medicine, Urology, 2006-2012
  • UC San Francisco School of Medicine, Chief Resident, 2011-2012
  • American Urologic Association
  • Western Section AUA
  • American Board of Urology
  • Endourological Society
  • American Association of Clinical Urologists
  • Fellow, American College of Surgeons
  • Board Member, Cancer Support Community, Redondo Beach
  • Robotic and Laparoscopic Surgery
  • Minimally Invasive Prostate Procedures
  • General Urology
  • Kidney Stones
  • Prostate Cancer, Localized and Advanced
  • Kidney Cancer
  • Bladder Cancer
  • Testis Cancer
  • Incontinence
  • Overactive Bladder

 

  • Torrance Memorial Medical Center
  • Providence Little Company of Mary
  • Pacific Endo-Surgical Center
  • PRIME Surgical Center
  • 2011 – NORCAL Award for Basic Science Presentation, 2nd place
  • 2002 – American Liver Foundation Grant Recipient
  • 2000 – Chapman Trust Scholarship Recipient
  • 1997 – NIH Pre-Doctoral Research Training Award Recipient
  • 1995 – American Diabetes Association Grant Recipient
  • 2006 – Academy of Achievement Invitee
  • 1997 – Phi Beta Kappa, Stanford University

Flechner L*, Koo S*, Qi L, Zhang X, Screaton R, Jeffries S, Hedrick S, Xu W, Boussouar F, Brindle P, Takemori H, Montminy M. The CREB Coactivator TORC2 is a Key Regular of Fasting Glucose Metabolism. Nature 2005 Oct 20; vol 437:1109-1114.

Blaschko S, Snell G, Miller J, Chi T, Flechner L, Fakra S, Stoller M, Micro Architecture of Human Stones using Advanced Imaging Techniques: Insight into early stone pathogenesis. Submitted.

Smith JF, Shindel AW, Huang YC, Clavijo RI, Flechner L, Breyer BN, Eisenberg ML, Lue TF. Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease. Asian Journal of Andrology 2010 Nov 22.

Flechner L, Tseng T, Understanding results: P-values, confidence intervals, and numbers needed to treat.

Indian Journal of Urology, Oct-Dec 2011, Vol 27: 532-534.

Stewart R, Flechner L, Montminy M, Berdeaux R, CREB is activated by muscle injury and promotes muscles regeneration. PLoS One. 2011;6(9):e24714 Sep 13.

Duclos A, Flechner LM, Faiman C, Flechner SM. Post-transplant diabetes mellitus: risk reduction strategies in the elderly. Drugs Aging. 2006 Feb 15;81(3):335-41.

Araki M, Flechner S, Ismail H, Flechner L, Zhou L, Derweesh I, Goldfard D, Modlin C, Krishnamurthi V, Faiman C. Posttransplant diabetes mellitus (PTDM) in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation. 2006 Feb 15; 81(3):335-341.

Best JL, Amezcua CA, Mayr B, Flechner L, Murawsky CM, Emerson B, Zor T, Gardner KH, Montminy M, Identification of small-molecule antagonists that inhibit an activator: coactivator interaction. Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17622-7.

Conkright MD, Guzman E, Flechner L, Su AI, Hogenesch JB, Montminy M., Genome-wide analysis of CREB target genes reveals a core promoter requirement for cAMP responsiveness. Molecular Cell. 2003 Apr;11(4):1101-8.

Li W, Hyun T, Heller M, Yam A, Flechner L, Pierce JH, Rudikoff S., Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumor growth. Cancer Res. 2000 Jul 15;60(14):3909-15.

Li W, Zhang J, Flechner L, Hyun T, Yam A, Franke TF, Pierce JH., Protein kinase C-alpha overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawal. Oncogene. 1999 Nov 11;18(47):6564-72.

Soon L, Flechner L, Gutkind JS, Wang LH, Baserga R, Pierce JH, Li W., Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression. Mol Cell Biol. 1999 May;19(5):3816-28.

Li W, Jiang YX, Zhang J, Soon L, Flechner L, Kapoor V, Pierce JH, Wang LH., Protein kinase C-delta is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation. Mol Cell Biol. 1998 Oct;18(10):5888-98.